Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitalangio1 Phase 1 Study in Healthy Volunteers
NCT07618351Phase 1Completed
- Sponsor
- Peking University First Hospital
- Start
- Jun 2023
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in venous thromboembolism (VTE), thrombosis and cardiovascular disease (CVD) (3 arms), sponsored by Peking University First Hospital. Primary endpoints: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs), Maximum Observed Plasma Concentration at 72 hours and 2 more. Started Jun 2023; status: completed.
02
Conditions
venous thromboembolism (VTE)thrombosiscardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT07618351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07618351.